Fate Therapeutics Inc (FATE) — Cash Flow-to-Debt Ratio
Fate Therapeutics Inc (FATE) has a Cash Flow-to-Debt Ratio of -0.22x as of September 2025, meaning its operating cash flow of $-24.37 Million could theoretically repay 0% of its total liabilities ($109.61 Million) in one year. See Fate Therapeutics Inc (FATE) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Fate Therapeutics Inc Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Fate Therapeutics Inc across 14 annual periods. Also explore net asset growth rate of Fate Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Fate Therapeutics Inc (2011–2024)
Year-by-year debt coverage analysis for Fate Therapeutics Inc. For market capitalisation and broader financial context, see market cap of Fate Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.01x | $-122.87 Million | $121.97 Million | ▼ -5.0% |
| 2023 | -0.96x | $-132.26 Million | $137.80 Million | ▲ +14.3% |
| 2022 | -1.12x | $-248.21 Million | $221.62 Million | ▼ -66.8% |
| 2021 | -0.67x | $-162.87 Million | $242.62 Million | ▼ -307.3% |
| 2020 | -0.16x | $-39.23 Million | $238.01 Million | ▲ +88.6% |
| 2019 | -1.45x | $-83.17 Million | $57.52 Million | ▼ -96.7% |
| 2018 | -0.74x | $-38.65 Million | $52.56 Million | ▲ +44.0% |
| 2017 | -1.31x | $-36.91 Million | $28.10 Million | ▲ +3.6% |
| 2016 | -1.36x | $-29.82 Million | $21.89 Million | ▼ -121.5% |
| 2015 | -0.61x | $-18.40 Million | $29.92 Million | ▲ +37.3% |
| 2014 | -0.98x | $-22.42 Million | $22.86 Million | ▲ +69.8% |
| 2013 | -3.25x | $-15.37 Million | $4.74 Million | ▼ -1462.9% |
| 2012 | -0.21x | $-13.27 Million | $63.90 Million | ▼ -0.1% |
| 2011 | -0.21x | $-12.14 Million | $58.53 Million | — |